3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1
1
Status
Active not recruiting
7
Recruiting
2
Suspended
1
Not yet recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
1
Genitourinary
1
Conditions
Lung Diseases
1
Kidney Neoplasms
1
Erythrocytosis, Familial, 4
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Specimen Handling
125
pembrolizumab
123
Magnetic Resonance Spectroscopy
108
Carboplatin
89
Cyclophosphamide
80
Biopsy
69
Cisplatin
67
Paclitaxel
61
Bevacizumab
56
Gemcitabine
54
Nivolumab
49
fludarabine
48
Dexamethasone
41
Rituximab
39
Pemetrexed
39
Fluorouracil
39
Radiotherapy
37
Doxorubicin
37
atezolizumab
36
Docetaxel
36
Leucovorin
35
Oxaliplatin
32
Capecitabine
32
venetoclax
31
Temozolomide
29
Prednisone
29
durvalumab
27
Standard of Care
27
Radiation
27
Letrozole
27
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recruiting
×
zimberelimab
×
30 days
×
Clear all
NCT05536141
2026-06-01
ARC-20
Arcus Biosciences, Inc.
Phase 1
Recruiting
362 enrolled
NCT06431633
2026-05-18
ARIAN
Fundación GECP
Phase 3
Recruiting
129 enrolled